FDA Approves Secukinumab for Pediatric HS, Creating First IL-17A Option for Adolescents

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of moderate to severe hidradenitis suppurativa (HS) in patients aged 12 years and older who weigh at least 30 kg, marking the first time an IL-17A inhibitor has received regulatory clearance for a pediatric HS population.¹ The approval, announced by Novartis, extends an indication that already existed in adults and positions secukinumab as a uniquely differentiated option in an age group where, until now, biologic therapy options were severely constrained.²

The Evidentiary Basis

The approval pathway here reflects a regulatory approach that is worth understanding in clinical context. Because conducting full double-blind, placebo-controlled trials in pediatric HS is both ethically complex and practically challenging — given the relatively small pool of eligible adolescent patients — the FDA accepted a package built on pharmacokinetic modeling extrapolated from the adult HS trials (SUNSHINE and SUNRISE) alongside PK data from pediatric psoriasis and enthesitis-related arthritis studies, where secukinumab is already approved in younger patients.³

Critically, the dosing analysis predicted that weight-adjusted secukinumab dosing in adolescents can reproduce drug exposure levels comparable to those achieved in adult HS patients, the population for whom the clinical benefit has been well established. This is not an unusual pathway for pediatric indications with a strong adult evidence base and known PK predictability, and the FDA's willingness to accept it signals confidence in the underlying mechanistic data.

Clinical Positioning

Secukinumab's mechanism is worth emphasizing in this context. Unlike TNF-alpha inhibitors, which have been used off-label in HS, IL-17A inhibition targets a cytokine that is particularly elevated in HS lesional tissue and has been tied more directly to the neutrophilic infiltration and keratinocyte dysregulation that characterize active disease. Whether this mechanistic specificity translates to meaningfully different clinical outcomes in the adolescent population compared to existing approaches remains to be fully characterized in real-world use, but the pathway gives clinicians a biologic option grounded in HS-relevant immunopathology rather than extrapolated from other indications.

The distinct mechanism also matters for sequencing decisions. Patients who have failed or are intolerant of TNF inhibitors — or for whom there is concern about class-specific adverse effects — now have an alternative biologic that does not share the same target. For a patient population that, if onset occurs at 13 or 14, may require decades of therapy management, preserving mechanistic diversity in the treatment algorithm is not trivial.

Dosing Considerations in Adolescents

The 30 kg weight threshold and individualized, weight-based dosing parameters in the label reflect the practical realities of treating a more heterogeneous patient population than is typical in adult dermatology. Clinicians managing adolescent patients will need to integrate standard monitoring protocols alongside age-specific considerations around immunosuppression, vaccination status, and the potential for rapidly changing body weight — factors that can influence dosing adjustments over time in ways less commonly encountered in adult practice.

Long-Term Safety Profile

One of the underappreciated advantages of secukinumab entering the pediatric HS space is the volume of existing safety data behind the molecule. With over 1.8 million treated patients worldwide since its 2015 launch, a post-marketing safety record spanning more than a decade, and approval across multiple indications in both adult and pediatric populations including psoriasis and juvenile psoriatic arthritis, the risk-benefit framework for secukinumab is substantially better characterized than it would be for a novel agent. For families and clinicians navigating the decision to initiate biologic therapy in a teenager, that accumulated real-world data carries meaningful weight.

Why This Approval Matters

HS does not wait for adulthood. More than half of patients develop their first symptoms during adolescence, yet the approved treatment landscape had not kept pace with the disease's demographic reality. The condition's chronic, progressive nature, marked by recurrent inflammatory nodules, sinus tract formation, and ultimately irreversible scarring, means that the years between first presentation and effective treatment carry disproportionate consequences for younger patients, not only physically but in terms of psychological development, self-image, and social functioning.

Historically, the diagnostic latency alone in HS averages close to a decade. For an adolescent presenting with perianal, axillary, or inguinal lesions, delayed recognition compounds the morbidity. The new secukinumab label acknowledges this reality directly, and the approval comes with weight-based dosing parameters specifically designed for the pediatric context — a detail that reflects deliberate formulation planning rather than a blanket label extension.

Looking Ahead

Whether this approval catalyzes broader industry attention to adolescent HS remains to be seen, but it sets an important precedent. The condition's impact during formative developmental years — its relationship to depression, social withdrawal, and diminished quality of life — makes earlier, effective intervention a genuine clinical and public health priority. Real-world data from adolescent patients treated under the new label will ultimately determine how secukinumab performs outside the controlled conditions that informed its approval, and that evidence base will be important for refining treatment guidelines in what has historically been an underserved patient population.

References

1. Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. News release. Novartis. Published March 13, 2026. Accessed March 13, 2026. https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa
2. Roesler J, Gregory A, Rehmus W. Pediatric hidradenitis suppurativa: an overview. Skin Therapy Lett. 2025;30(1):1-4.
3. Kimball AB, Bechara FG, Badat A, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025;192(4):629-640. doi:10.1093/bjd/ljae469